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In vivoexposure to microorganisms resident in the oral cavity is considered as a possible cause of Kawasaki
disease (KD), and some epitopes derived from streptococci display homology with Factor H of Complement.
Additionally, calprotectin, a major calcium binding protein released by neutrophils and activated monocytes,
could be directly involved in endothelial damage occurring in KD. The aim of our study is to evaluate the
percentages of IFN-y+ and/or TNF-a+ lymphocytes and double positive calprotectinffNF-a monocytes
(CD14+) after in vitro stimulation with streptococcal- and/or Factor H-derived peptides, in patients with
acute KD. Peripheral Blood Mononuclear Cells (PBMCs) obtained from KD patients and febrile controls
were stimulated in vitro with peptides. After culture, cells were collected, stained with fluorochrome-labelled
monoclonal antibodies against CD3, CD14, calprotectin, IFN-y and TNF-a, and cytofluorimetric analyses
were performed. Our results showed increased percentages of TNF-a+IIFN-y+ lymphocytes in KD patients
in respect to controls when PBMCs were stimulated with streptococcal or Factor H-derived epitopes.
In addition, also calprotectin+rrNF-a+ monocytes from KD patients were activated after PBMC in vitro
stimulation. These findings lead us to speculate that some peptides, derived from oral streptococci and
cross-reactive with the human Factor H of Complement, could induce lymphocyte and monocyte activation
potentially involved in the pathogenesis of KD. Our results should be confirmed by further studies enrolling
more patients and controls than those analyzed in our study.
Kawasaki disease (KD) is an acute febrile
illness that primarily arises in infancy and early
childhood characterized by diffuse vasculitis of
medium-sized arteries. Clinical features consist of
fever accompanied by lymphadenopathy, skin rash,
conjunctivitis, oropharyngeal mucosal changes and
extremity changes (l). Diagnostic criteria, used
in clinical approach to patients may, however, be
inadequate, and early diagnosis frequently remains
challenging, with high risk of coronary damage. In
fact, in most cases it is a limited illness resolving in
few days after fever onset, but without appropriate
intervention coronary artery aneurysms can develop
in about 15-25% of the patients (1). The acute
phase of KD is characterized by a deficiency of
suppressor T cells, marked activation of the immune
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system and increased secretion of pro-inflammatory
cytokines by immune effector cells, such as TNF-a,
IFN-y, IL-I~, IL-6 (1-3). Another hematological
alteration commonly found in KD is the increase
of peripheral blood monocytes (3). Moreover, some
studies reported the increased production of TNF-
a, and in particular its role in the inflammation of
arteries, as immunological marker of acute phase of
KD. In fact, infliximab and etanercept, monoclonal
antibodies blocking the biological activity of
TNF-u, were used for refractory KD patients and
were reported to be effective and safe (4, 5). An
efficient therapy, based on intravenous infusion of
high doses of immunoglobulins (lVIG), has been
found to effectively reduce the inflammation and the
incidence of coronary artery lesions (6).
Recently, it has been shown that myeloid-related
proteins (MRP-8 and MRP-14) of SlOO- family,
the major calcium-binding proteins secreted by
activated neutrophils and monocytes, control
myeloid cell function and inflammation, in part,
through activation ofToll-like receptor-4. The MRP-
8/MRP-14 complex binds specifically to human
microvascular endothelial cells through heparan
sulfate proteoglycans and novel carboxylated N-
glycans, contributing to cause inflammation in acute
vascular lesions occurring in several diseases such
as KD (7). Moreover, there is increasing evidence
that streptococci infections and the upregulation
of calprotectin, one of the major calcium-binding
proteins, may directly and indirectly induce not only
inflammation but also modifications affecting the
microvascular wall in acute vasculitis syndromes
(2, 7).
Several years ago, scientists identified as a
possible cause of KD the exposure to microbial
agents derived from organisms resident in the oral
cavity such as Streptococcus (S.) oralis, S. mitis, S.
sanguinis and S. parasanguinis (8). Additionally,
it has been shown that phosphoglyceratemutase
(gpml) of Candida albicans and Saccharomyces
cerevisiae are Factor H- and FHL-I-binding protein
(9).
Following this background, we analysed the
percentages of intracellular calprotectin and/or
TNF-a positive monocytes and the activation of
T lymphocytes after in vitro exposure to several
commensal streptococci- and/or Factor H-derived
peptides, as a novel immune correlate ofinflammation
and possible cause of endothelium damage mainly
occurring in the acute phase of KD. To evaluate the
association between the degree of inflammation and
the alteration of micro-vascular wall, we analysed
TNF-a and IFN-y positive lymphocytes and the
production of calprotectin and TNF-a in CDI4+
cells, probably involved in the endothelial damage
suggestive of KD after lymphocyte peptide specific
activation.
MATERIALS AND METHODS
Patients
In this study we enrolled 8 children (5M, 3F),
affected by Kawasaki disease, diagnosed following
international criteria (10) and recruited during the years
2010-2011. At diagnosis, their age ranged from 4 to 45
months. A parents' informed consent was obtained for
patients and for febrile controls, as suggested by the
bioethics committee of Meyer Hospital, Florence and
Paolo Giaccone University Hospital, Palermo. All the
KD patients, in addition to fever and the classic criteria,
showed signs of cardiac involvement, specifically
pericarditis in two cases and coronary lesions in the
other six. Only two of them improved with a single
cycle of intravenous immunoglobulins, while the other
six needed a second cycle; one of them also needed
intravenous corticosteroids and infliximab. As this patient
did not respond to IVIG therapy, we excluded the results
obtained by the PBMCs of this patient from the patient
data. Heparinised blood samples from KD patients were
collected before IVIG therapy. Laboratory tests showed in
all cases anaemia, leukocytosis (present also in controls)
thrombocytosis and elevation of acute phase indexes. All
of the children, ultimately, had total remission of clinical
signs and symptoms, and also had resolution of coronary
alterations. Febrile patients with documented viral or
bacterial infections (4M and 4F, age-matched with KD
patients) were also enrolled as controls. All patients and
controls were typed for HLA DR B1 alleles resulting
heterozygous by Low Resolution SSO test (One Lambda,
California, USA) as shown in Table I.
Peptides
A total of 4 peptides derived from the sequence
of the proteins of Streptococcus sanguinis (p28,#1(or
#2010),#4) and chain A, solution structure of human
complement factor H (#42), were acquired from
LIONEX Diagnostics & Therapeutics (Braunshweig,
Germany). Peptide #1 (EKSWRLNERHYGGLTGKN
Int. J. IrnrnnnopathoI. Pharrnacol. 101
Table I. Typing results ofpatients andfebrile controls obtained with low resolution kit (One Lambda, California, USA).
Patient 1 DR B1 030l/DR 0401 Febrile Control 1 DR 0401/DR 0301
Patient 2 DR BI 03011 DR 0401 Febrile Control 2 DR 070l/DR 0301
Patient 3 DR 040l/DR 0101 Febrile Control 3 DR 1501/DR 090 I
Patient 4 DR 070l/DR 0301 Febrile Control 4 DR 080l/DR 1101
Patient 5 DR 01Ol/DR 0701 Febrile Control 5 DR 040l/DR 0301
Patient 6 DR 1101/DR 0901 Febrile Control 6 DR 0101/DR 0301
Patient 7 DR 1501/DR 1101 Febrile Control 7 DR 11Ol/DR 1501
Patient 8 DR 080l/DR 1501 Febrile Control 8 DR 040l/DR 0701
KAEAAE), peptide #4 (gpml like-molecules derived
from S. sanguinis) (YDVLPPAMPRDDEYSAHTDRRY
AS), peptide #42 (chain A, solution structure of human
complement factor H), p28 (LNDTLDYERHDGYESNT
GSTTGS) and #42 (LNDTLDYECDGYESNTGSTGS).
Analysis of peptide sequences showed high homology
between p28 and the human complement factor H-derived
peptide #42 [identities = 20/23aminoacids (87%); http:
//blast.ncbi.nlm.nih.gov/Blast]. We used a bioinformatics
software analysis (through SYFPEITHY website) to detect
the highest binding scores of the proteins with the most
frequent HLA DRBI alleles in Caucasians. The peptides
with maximal binding capacity with the most frequent
HLA DRB I alleles were p28 and #42 (derived from chain
A of the human Complement factor H), that display a
high degree of homology. These peptides were chosen
also because they bind with high score many HLA-DRBI
alleles frequently detected in Caucasians. In particular,
p28 epitopes display the highest score of binding with
HLA DRBI alleles than the other epitopes used. Because
the sequences of these proteins show a high degree of
homology with some "immunodominant" epitopes of S.
sanguinis, we analysed in vitro responses of Peripheral
Blood Mononuclear Cells (PBMCs) to these epitopes. We
used these proteins and peptides to understand whether
some residues are involved in lymphocyte activation. The
purity rate of peptides was 95% and their homogeneity
was confirmed by analytical reverse-phase high-
performance liquid chromatography, mass spectroscopy,
and aminoacid composition analysis.
Cell cultures and intracellular staining
PBMCs were isolated from heparinized blood by
centrifugation on Ficoll-Hypaque (Pharmacia). The
medium used throughout was RPMI 1640 (Invitrogen
Life Technologies) supplemented with 10% heat-
inactivated fetal cow serum (FCS), 2 mM L-glutamine, 20
mM HEPES, 100U/ml penicillin, 1001lg/ml streptomycin,
5 x 10-5 M 2-ME. PBMCs (l06/ml) were stimulated with
peptides (25Ilg/ml, final concentration) for 16 h at 37°C
in 5% CO2; 3 flM monensin (Sigma, Massachussetts,
USA) was added after 2 h of incubation as Golgi blocker.
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PBMCs cultured without any stimulus (only complete
medium) were used as negative control and unstimulated
PBMCs were evaluated to assess nonspecific/background
cytokine production. These cells were also cultured for
16 h at 37°C in 5% CO2 and 3 !J,M monensin was added
after 2 h of incubation, together with other cells, as above-
mentioned. All the cells were then harvested, washed
and stained with anti-CD3-FITC (cloneUCHTl,BD
Pharmingen, San Jose', CA, USA), anti-CD4-PerCP5.5
(clone RPA-T4, BD Pharmingen, San Jose', CA, USA),
anti-CD8-PerCP5.5 (clone RPA-T8, BD Pharmingen, San
Jose, CA, USA) and anti-CDl4-PerCP5.5 (clone 6lD3,
eBiosciences, San Diego, CA, USA), both diluted in
incubation buffer, containing PBS, 1% FCS and 0.1% Na
azide, for 30 min at 4°C. Cells were washed twice in PBS-
1% FCS and then fixed and permeabilized (Fix and Perm
kit, BD Pharmingen, San Jose, CA, USA) to perform the
intracellular staining with anti-TNF-a-PE (clone JID9,
Ancell Corporation, Bayport, USA), anti-IFN-y-APC
(clone B2, BD Pharmingen, San Jose, CA, USA), anti-
calprotectin-FITC (clone 27EIO, Hycult biotech, Uden,
The Netherlands) and isotype-matched control mAb
(eBiosciences, San Diego, CA). 100.000 events were
acquired and analysed for each sample by FACS Calibur.
Statistics
Values obtained from intracellular staining of PBMCs
cultured only with RPMI plus 10% FCS were used as
negative controls and subtracted from those obtained
from PBMCs stimulated with peptides. Student's t and
Mann-Whitney tests were used to determine statistical
significances comparing data obtained from age-matched
patients and controls. Values of p<0.05 were considered
significant.
RESULTS
Our results showed increased mean percentages
of CD3 positive cells producing IFN-y and/or TNF-
a in KD patients in respect to febrile controls when
stimulated with peptides. The highest percentages
of activated lymphocytes (IFN-y+ and/or TNF-a+)
were found after stimulation with p28 and #42
(Fig. I , A and B), probably it may depend on the
affinity and avidity of a single epitope. The mean
percentages of IFN-y+ and/or TNF-a+CD3+ were
statistically significant (p< 0.05) among stimulated
cells of KD patients and controls (Fig. lA). To
characterize the phenotype of IFN-y+ and/or TNF-
a+ CDY T cells, CD4 or CD8 expression on these
cells was analyzed by triple staining of these cells.
Mainly CD3+CD4+IFN-y+ and/or TNF-a+ cells were
detected (91%) (data not shown). Fig. IB shows
representative dot plot analysis ofCD3+ cells from a
patient and a control, after culture with p28.
Additionally, patients with acute KD showed
increased mean percentages of calprotectin'/Cl'rl-l'
cells in the same culture conditions. On the contrary,
age-matched febrile controls did not show any
increase of intracellular calprotectin in CDI4+
cells (Fig. 2A). The differences between the mean
percentages of CD 14+/calprotectin+ cells from
patients and controls were statistically significant.
A representative dot plot analysis of CDI4+/
calprotectin' obtained from one KD patient and one
febrile control are shown in Fig. 2B.
We also analysed the Mean Fluorescence Intensity
(MFI) of intracellular calprotectin expressed in
CDI4+ and we found higher MFI in patients respect
to control for all the peptides tested (Fig.3).
These results suggest an important role for
activated CD3 positive cells, specifically stimulated
with peptides derived from S. sanguinis and/or
Factor-H, in the expansion of calprotectin'/Cfrl-l'
monocytes. Considering this subset of monocytes as
a possible player in the pathogenesis of endothelial
damage, we also analysed TNF-a production in
calprotectin positive monocytes.. In fact, detection
of a single molecule, such as TNF-a or calprotectin,
does not fully reflect the functional potential of the
cells involved in the pathogenesis of the disease.
Statistically significant higher mean percentages
of TNF-a+/calprotectin+/CDI4+ cells were observed
(p< 0.05) after in vitro stimulation of PBMCs with
p28 and #42 peptides in all patient samples tested
when compared to those obtained from febrile
controls (Fig 2C). A representative dot plot analysis
ofcalprotectin/TNF-a positive cells, gated on CD 14+
population, of one KD patient and febrile control is
shown in Fig.2D.
Regarding the strength of PBMCs' response to
the epitopes, we detected a maximal activation of
lymphocytes and of double positive calprotectin/
TNF-a CDI4+ cells, when p28 and #42 (degree
of homology of 87%) were used. These data
demonstrate, for the first time to our knowledge,
that calprotectin'Zl'Nl--n' CDI4+ cells could be
associated with the acute phase of KD, suggesting a
pathogenetic role for this subset in this vasculitis.
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Fig. 1. A) IFN-y and/or TNF-a production by CD3+ lymphocytes after PBMC culture with specific peptides. The
histograms show highest mean percentages ofactivated lymphocytes (producing IFN-y and/or TNF-a) in KD patients in
respect to controls, (*p<0.05). B) Dot plot analysis ofIFN-y/TNF-a positive cells among CD3 positive lymphocytes of
one representative KD patient and one age-matchedfebrile control. Error bars represent standard deviation.
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Fig. 2. A) Comparison ofthe frequencies ofCD14+/calprotectin: cells in peripheral bloodfrom KD patients with acute
disease before starting therapy and febrile controls. The histograms show highest mean percentages of intracellular
calprotectin in patients with acute KD; the lowest mean percentages were found in controls, * p<0.05. B) Dot plot
analysis ofCD14+/calprotectin: cell populations ofone representative KD patient and one febrile control. C) Increased
mean percentages of double positive calprotectin/TNF-a CD14+ cells after peptide-specific stimulation in patients in
respect to febrile controls, *p<O.05. D) Dot plot analysis ofCD14+calprotectin/TNF-a positive cell populations ofone
representative KD patient and one age-matchedfebrile control. Error bars represent standard deviations.
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Fig. 3. An MFI analysis of Clrl-t'calprotectin' cells was assessed to compare the values between patients (dark grey
columns) and controls (grey columns). All the differences were statistically significant (p<O.05).
DISCUSSION
CDI4+ cells play a critical role in several
inflammatory disorders (11, 12), but their role has
gained increasing attention also in KD pathogenesis
(13).ln the present study, we investigated lymphocyte
activation after stimulation of PBMCs with different
peptides derived from S.sanguinis and Factor H of
Complement, and calprotectin and TNF-a double
positive monocytes obtained from KD patients and
febrile controls. Our results showed CD3 positive
cell activation after culture with peptides derived
from oral streptococci in KD patients in respect to
the control group. We also demonstrated, for the
first time, that KD patients have high percentages of
calprotectin" cells and double positive calprotectinl
TNF-a CDI4+ cells. These findings lead us to
speculate that some peptides derived from oral
streptococci and the human Factor H ofComplement
can be involved in the pathogenesis ofKD, probably
through production of immunobiologically active
extracellular products (i.e. IFN-y and TNF-a)
by lymphocytes that finally promote monocyte
activation. Our data also suggest that double positive
calprotectinlTNF-a positive monocytes could play
an important role in triggering the vasculitis in acute
KD. Regarding the strength of PBMCs' response
to the epitopes, we detect a maximal activation of
lymphocytes, and the sequential increase (probably
due to IFN-y and/or TNF-a release) of double
positive calprotectinlTNF-a CDI4+ cells, when p28
and #42 (degree of homology of 87%) were used.
These two epitopes could have aminoacidic residues
providing anchoring sites for MHC and/or TCRs
binding, preferentially involved in the activation
of T cell. These data demonstrate, for the first time
to our knowledge, that calprotectin'Zl'Nf-u' CDI4+
cells could be associated to the acute phase of KD,
suggesting a pathogenetic role of this subset in this
vasculitis. Clearly we cannot exclude that other
cytokines, such as IL-l, IFN-y and/or IL-6 could
be secreted by activated monocytes causing, in
synergy with calprotectin and TNF-a, endothelial
damage. Thus, a microbial agent, cross-reacting
with endogenous Factor H of Complement, can
stimulate the production ofcalcium-binding proteins
that could participate, synergistically with TNF-a, to
the vasculitis. Our data strengthen Foell's results (2),
suggesting that calcium-binding proteins could serve
as a novel target for future therapeutic intervention
in inflammatory disorders, and also that calprotectinl
TNF-a positive monocytes can be used as markers to
monitor disease course and therapy.
In conclusion, calprotectint/l'Nf-u' monocytes,
induced by IFN-y+/TNF-a+ lymphocytes activated by
p28 and #42 epitopes, could represent an important
effector cell subset involved in the generation ofacute
KD. We hypothesize that this cell subset could be used
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as a marker of acute KD. Novel immunotherapeutic
approaches, based on the combination of anti-
calprotectin and anti-TNF-a agents, could be
suggested for an efficient KD therapy. Moreover,
other studies will be necessary to better characterize
these cells and their role in the disease.
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